We are live on ! Find out more
SI

Sofinnova Investments Portfolio holdings

AUM $2.63B
1-Year Est. Return 117.41%
This Fund
S&P 500
This Quarter Est. Return
+0.58%
1 Year Est. Return
+117.41%
3 Year Est. Return
+428.82%
5 Year Est. Return
+748.21%
10 Year Est. Return
–
AUM
$1.66B
AUM Growth
-$16.4M
Cap. Flow
+$51.9M
Cap. Flow %
3.12%
Top 10 Hldgs %
60%
Holding
84
New
16
Increased
17
Reduced
16
Closed
20

Top Buys

Rank Stock Value
1
BOLT icon
Bolt Biotherapeutics
BOLT
+$89.6M
2
NXTC icon
NextCure
NXTC
+$32.2M
3
LLY icon
Eli Lilly
LLY
+$28.1M
4
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$27.3M
5
ALGN icon
Align Technology
ALGN
+$25.2M

Top Sells

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$89.4M
2
ABBV icon
AbbVie
ABBV
+$31.5M
3
AMGN icon
Amgen
AMGN
+$30M
4
UTHR icon
United Therapeutics
UTHR
+$22.2M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$14.4M

Sector Composition

Rank Sector Weight
1 Healthcare 93.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NTRA icon
1
Natera
NTRA
$37.5B
$315M 18.93%
3,100,560
– –
KRTX
2
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$235M 14.11%
1,952,441
– –
BOLT icon
3
Bolt Biotherapeutics
BOLT
$7.36M
$90.6M 5.45%
+137,722
New +$89.6M
ASND icon
4
Ascendis Pharma A/S
ASND
$16.7B
$67.3M 4.04%
521,923
-587,951
-53% -$89.4M
YMAB
5
DELISTED
Y-mAbs Therapeutics
YMAB
$66.4M 3.99%
2,194,278
– –
AZN icon
6
AstraZeneca
AZN
$263B
$51.5M 3.1%
517,866
+96,566
+23% +$9.71M
XLV icon
7
PUT
State Street Health Care Select Sector SPDR ETF
XLV
$42.1B
$46.7M 2.81%
400,000
+100,000
+33% +$11.5M
CMPI
8
DELISTED
Checkmate Pharmaceuticals, Inc. Common Stock
CMPI
$43.8M 2.63%
3,606,707
– –
JAZZ icon
9
Jazz Pharmaceuticals
JAZZ
$15.9B
$42.1M 2.53%
255,928
+43,017
+20% +$7.08M
INZY
10
DELISTED
Inozyme Pharma
INZY
$40.2M 2.41%
2,028,308
– –
UTHR icon
11
United Therapeutics
UTHR
$26.3B
$36M 2.16%
215,054
-132,847
-38% -$22.2M
LLY icon
12
Eli Lilly
LLY
$1.07T
$33.7M 2.03%
180,501
+143,592
+389% +$28.1M
NCNA
13
NuCana
NCNA
$5.37M
$27.9M 1.68%
1,120
– –
MRUS
14
DELISTED
Merus
MRUS
$27.4M 1.65%
1,311,039
– –
GRTX
15
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
$27.2M 1.64%
3,083,712
– –
NXTC icon
16
NextCure
NXTC
$17.3M
$26.7M 1.61%
+222,655
New +$32.2M
ALGN icon
17
Align Technology
ALGN
$12B
$24.6M 1.48%
+45,500
New +$25.2M
XLRN
18
DELISTED
Acceleron Pharma
XLRN
$24.2M 1.46%
178,538
+141,850
+387% +$18.3M
RETA
19
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$23.8M 1.43%
238,520
+89,583
+60% +$10.4M
MRTX
20
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$23.6M 1.42%
+138,030
New +$27.3M
ITCI
21
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$22.2M 1.34%
655,001
-193,161
-23% -$6.7M
PTCT icon
22
PTC Therapeutics
PTCT
$6.37B
$22.1M 1.33%
466,840
+150,362
+48% +$8.93M
INSM icon
23
Insmed
INSM
$23.2B
$21.1M 1.27%
618,950
+309,288
+100% +$11.8M
AKUS
24
DELISTED
Akouos Inc
AKUS
$21M 1.26%
1,515,074
– –
GILD icon
25
CALL
Gilead Sciences
GILD
$161B
$19.4M 1.17%
+300,000
New +$19.3M
1
2 3 4

Similar funds

WWM
Western Wealth Management Golden, Colorado $2.63B AUM 21.3% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $2.63B AUM 20.53% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return
WCA
Waratah Capital Advisors Toronto, Ontario, Canada $2.63B AUM 76.33% 1-Year Est. Return
ACM
Advance Capital Management Southfield, Michigan $2.64B AUM 13.57% 1-Year Est. Return
NIG
NFJ Investment Group Dallas, Texas $2.64B AUM 23.86% 1-Year Est. Return
WBG
Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Sofinnova Investments's Q1 2021 Portfolio in Review

As of Q1 2021, Sofinnova Investments held 84 positions worth $1.66B, down 0.98% from $1.68B the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Sofinnova Investments deployed $51.9M of net new capital in Q1 2021, opening 16 new positions and adding to 17 existing holdings. Its largest new stake was Bolt Biotherapeutics: 137,722 shares worth $90.6M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 92% a quarter earlier.

On the sell side, the largest reduction was Ascendis Pharma A/S, an estimated $89.4M trimmed.

  • Sofinnova Investments's largest Q1 2021 buy was Bolt Biotherapeutics: 137,722 shares worth $90.6M.
  • Sofinnova Investments added most to Eli Lilly in Q1 2021, an estimated $28.1M increase.
  • Sofinnova Investments's biggest Q1 2021 reduction was Ascendis Pharma A/S, cutting an estimated $89.4M.
  • Sofinnova Investments fully exited AbbVie in Q1 2021, selling an estimated $31.5M.
  • Sofinnova Investments's ten largest holdings make up 60% of its $1.66B portfolio in Q1 2021.
  • Sofinnova Investments opened 16 new positions and closed 20 in Q1 2021.
  • Sofinnova Investments's portfolio value fell 0.98% quarter-over-quarter to $1.66B.

Based on Sofinnova Investments's 13F filing for Q1 2021, filed 14 May 2021.